(R)-3-{4-[1-(4-cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid | 385835-98-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-{4-[1-(4-cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
• 英文别名: (R)-3-{4-[1-(4-Cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionicacid；(2R)-3-[[4-[[4-cyclohexyl-N-[[3-methoxy-5-(trifluoromethyl)phenyl]carbamoyl]anilino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
• CAS: 385835-98-3
• 化学式: C₃₂H₃₄F₃N₃O₆
• 分子量: 613.634
• InChiKey: KOZDDXIYVDHLIC-MUUNZHRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (R)-3-{4-[1-(4-cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid ethyl ester 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以94%的产率得到(R)-3-{4-[1-(4-cyclohexylphenyl)-3-(3-methoxy-5-trifluoromethylphenyl)ureidomethyl]benzoylamino}-2-hydroxypropionic acid
  参考文献：
  名称：

  Novel Glucagon Receptor Antagonists with Improved Selectivity over the Glucose-Dependent Insulinotropic Polypeptide Receptor

  摘要：

  Optimization of a new series of small molecule human glucagon receptor (hGluR) antagonists is described. In the process of optimizing glucagon receptor antagonists, we counter-screened against the closeli related human gastric inhibitory polypeptide receptor (hGIPR), and through structure activity analysis, we obtained compounds with low nanomolar affinities toward the hGluR, which were selective against the hGIPR and the human glucagon-like peptide-1 receptor (hGLP-1R). In the best cases, we obtained a >50 fold selectivity for the hGluR over the hGIPR and a > 1000 fold selectivity over the hGLP-1R. A potent and selective glucagon receptor antagonist was demonstrated to inhibit glucagon-induced glycogenolysis in primary rat hepatocytes as well as to lower glucagon-induced hyperolycemia in Sprague-Dawley rats. Furthermore. the compound was shown to lower blood glucose in the ob/ob mouse after oral dosing.

  DOI：

  10.1021/jm7015599

文献信息

• [EN] SALTS AND SOLVATES OF GLUCAGON ANTAGONISTS<br/>[FR] SELS ET SOLVATES D'ANTAGONISTES DE GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO2004063147A1

  公开（公告）日：2004-07-29

  The invention provides salts and solvated of glucagon antagonists.

  这项发明提供了胰高血糖素拮抗剂的盐和溶剂化物。
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] ANTAGONISTES/AGONISTES INVERSES DU GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO2002000612A1

  公开（公告）日：2002-01-03

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

  一种新型化合物，其作用是对抗胰高血糖素激素对胰高血糖素受体的作用。由于这些化合物对胰高血糖素受体的拮抗作用，因此这些化合物可能适用于治疗和/或预防任何需要胰高血糖素拮抗作用的疾病和障碍，例如高血糖症、1型糖尿病、2型糖尿病、脂质代谢障碍和肥胖症。
• Glucagon antagonists/inverse agonists
  申请人：——

  公开号：US20040024045A1

  公开（公告）日：2004-02-05

  A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

  一种新型化合物，能够拮抗胰高血糖素在胰高血糖素受体上的作用。由于这些化合物能够拮抗胰高血糖素受体的作用，因此它们可能适用于治疗和/或预防任何需要拮抗胰高血糖素作用有益的疾病和疾病，例如高血糖症，1型糖尿病，2型糖尿病，脂质代谢紊乱，如血脂异常和肥胖症。
• US6562807B2
  申请人：——

  公开号：US6562807B2

  公开（公告）日：2003-05-13
• US6953812B2
  申请人：——

  公开号：US6953812B2

  公开（公告）日：2005-10-11